SUNPHARMA — Sun Pharmaceutical Industries Income Statement
0.000.00%
- IN₹3.63tn
- IN₹3.50tn
- IN₹484.97bn
- 92
- 13
- 91
- 77
Annual income statement for Sun Pharmaceutical Industries, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 328,375 | 334,981 | 386,545 | 438,857 | 484,969 |
Cost of Revenue | |||||
Gross Profit | 223,662 | 236,127 | 269,468 | 319,433 | 378,342 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 281,291 | 313,515 | 350,768 | 347,933 | 385,608 |
Operating Profit | 47,084 | 21,466 | 35,777 | 90,924 | 99,360 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 50,096 | 27,994 | 44,813 | 94,084 | 110,879 |
Provision for Income Taxes | |||||
Net Income After Taxes | 41,868 | 22,847 | 34,058 | 85,608 | 96,484 |
Minority Interest | |||||
Equity in Affiliates | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 37,649 | 29,038 | 32,727 | 84,736 | 95,764 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 37,649 | 29,038 | 32,727 | 84,736 | 95,764 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 16.5 | 26.7 | 28 | 36 | 41.7 |
Dividends per Share |